Will HIRA resume talk to grant benefits for anti-diabetic combo drugs?

Korea Biomedical Review

22 October 2020 - Three makers of SGLT-2 inhibiting anti-diabetic drugs said they would seek changes in approval conditions to allow their drugs to be used in combination with DPP-4 inhibitors in November.

The move draws attention to whether the state health insurance review agency will resume the discussion to approve insurance benefits for combo drugs mixing SGLT-2 inhibitors and DPP-4 inhibitors.

AstraZeneca, Boehringer Ingelheim, and MSD said they would apply for approval condition changes for SGLT-2 inhibitors as early as 3 November.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder